News

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a powerful and convenient new way to ward off infection in a wide range of ...
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...